Videos
Press Releases
22 Sep 2022
EORTC Quality of Life Group celebrating 40 years
31 Aug 2022
EORTC Item Library provides considerable coverage of CTCAE side effects, new study finds
27 Jun 2022
PRESS RELEASE: Better treatment for better health: lifting the veil on treatment optimisation
17 Mar 2022
MSD’s KEYTRUDA® (pembrolizumab) Significantly Improved Disease-Free Survival (DFS) Versus Placebo as Adjuvant Therapy in Patients With Stage IB-IIIA Non-Small Cell Lung Cancer (NSCLC) Regardless of PD-L1 Expression
Latest Newsletters
News
8 May 2024
EORTC/EMA workshop suggests an international way forward for treatment optimisation studies
29 Apr 2024
EORTC’s Participation at the ESTRO Congress 2024
29 Feb 2024
EORTC: Advancing research and treatment for rare cancers
22 Feb 2024
EORTC Fellowship Programme: celebrating more than 20 years of impactful collaboration
9 Feb 2024
Appointment of Malte Peters as EORTC Strategic Alliance Officer
7 Feb 2024
Unique series of workshops in partnership with the European Medicines Agency (EMA)
14 Dec 2023
EORTC launches a prominent clinical trial in older patients with locally advanced (LA) HNSCC (Head and Neck Squamous Cell Carcinoma)
6 Dec 2023
Seven IMMUcan abstracts selected for ESMO Immuno-Oncology Congress 2023
20 Nov 2023
EORTC Quality of Life measures integrated in CDISC
7 Nov 2023
EORTC and Immunocore are collaborating to launch the ATOM clinical trial of tebentafusp in Adjuvant Uveal Melanoma
